|Nombre||Título||Pagar||Ejecutado||Año de nacimiento|
|Mr. Mark T. Iwicki||Chairman, Pres & CEO||927.39k||N/D||1966|
|Mr. Eric L. Trachtenberg||Gen. Counsel, Chief Compliance Officer & Corp. Sec.||703.39k||N/D||1973|
|Dr. Kim Brazzell||Chief Medical Officer||643.9k||N/D||1953|
|Dr. Justin Hanes Ph.D.||Founder & Chair of the Scientific Advisory Board||N/D||N/D||N/D|
|Ms. Mary Reumuth CPA, CPA||CFO & Treasurer||N/D||N/D||1975|
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.
La calificación ISS Governance QuickScore de Kala Pharmaceuticals, Inc. a partir del 1 de abril de 2019 es 9. Las puntuaciones principales son Auditoría: 2; Junta: 10; Derechos del accionista: 8; Compensación: 8.